• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Washington Post Editorial Failure to Anticipate Vaccines & Tami Alternatives

  • Thread starter Thread starter GaudiaRay
  • Start date Start date
G

GaudiaRay

Guest
Another 1918?

Despite preparations, a flu pandemic could still kill millions of Americans.

Wednesday, November 22, 2006; Page A20

ON MONDAY, the Department of Health and Human Services released a progress report on its preparations for a flu pandemic in the United States. Not stressed, but nevertheless clear, was how much the country would rely on antiviral drugs such as Tamiflu, a drug that can reduce the severity of flu symptoms, to treat Americans while new vaccines were developed. Public health authorities are frantically stockpiling Tamiflu, and they hope to have more than 50 million courses of antiviral medication on hand by the end of 2008 to administer in the event of an outbreak.
But a report released by the World Health Organization earlier this month said that strains of the H5N1 "bird flu" virus -- a likely candidate for mutation into a pandemic flu -- might be developing resistance to Tamiflu and other antivirals. The influenza virus is unpredictable and quick to mutate. No one knows how, or how fast, the bird flu virus will change, so no one knows if the reported cases of Tamiflu resistance will remain isolated or if the virus will become increasingly more resistant to standard antivirals -- as it has with other drugs. But the country faces the possibility that its reserve of Tamiflu might not do much to counter a pandemic flu.

The federal government is also collecting doses of vaccines that protect against existing strains of the bird flu virus, though on a much smaller scale than its purchase of Tamiflu. These shots, the HHS report said, might eliminate or ease symptoms caused by new forms of the virus. But the WHO report was pessimistic about the effectiveness of the vaccines against strains of the virus they were not designed to fight.
In other words, if a pandemic flu began spreading tomorrow, the government's most effective strategies for saving lives could be old-fashioned quarantine and public education, techniques akin to those used during the great flu pandemic of 1918. It is not surprising, then, that the federal government currently estimates that as many as 2 million people could die if a virulent and contagious strain of flu hit the United States.
Given the capriciousness of the virus, says Columbia epidemiologist Stephen S. Morse, the government has "no silver bullet" in its arsenal. But HHS should consider investing heavily in technologies such as the reverse genetic engineering of flu vaccines, a process that promises to speed up vaccine production dramatically. The federal government should also focus more on aiding the World Health Organization's efforts to monitor avian flu and to improve the health infrastructure in Southeast Asia. Added American assistance to the understaffed WHO in Indonesia, Thailand and Vietnam could save many more American lives than 50 million courses of antivirals.
http://www.washingtonpost.com/wp-dyn/content/article/2006/11/21/AR2006112101442.html
 
Re: Washington Post Editorial Failure to Anticipate Vaccines & Tami Alternatives

<table summary="This table is for formatting only" border="0" cellpadding="4" cellspacing="0" width="100%"><tbody><tr><td align="left" valign="top" width="50%">FOR IMMEDIATE RELEASE
Monday, Nov. 20, 2006
</td> <td align="right" valign="top" width="50%"> Contact: HHS Press Office


</td> </tr> </tbody></table> HHS Buys Additional Vaccine for Potential Use in an Influenza Pandemic

HHS Secretary Mike Leavitt today announced the purchase of additional vaccine that could be used in the event of a potential influenza pandemic.
The department has awarded contracts totaling $199.45 million to three vaccine makers to manufacture 5.3 million 90-microgram doses of influenza vaccine designed to protect against the H5N1 influenza virus strain. The three awards include a $117.9 million contract to sanofi pasteur for 3.7 million doses, a $40.95 million contract to Novartis for 800,000 doses and a $40.6 million to GlaxoSmithKline for 800,000 doses.
"Having a stockpile of influenza vaccine that may offer protection against the H5N1 virus is an important part of our pandemic influenza preparedness plan," Secretary Leavitt said. "These contracts are a continuation of our aggressive multi-pronged approach to a potentially critical public health challenge."
At two 90-microgram doses per person, these purchases provide enough courses to vaccinate nearly 2.7 million people. Initial clinical studies of H5N1 vaccine in humans have shown that two 90-microgram doses of the vaccine are required to stimulate a level of immune response that researchers anticipate would provide protection for an individual against the H5N1 strains that have been spreading among birds in Asia. However, further clinical testing is underway, including the evaluation of techniques that may reduce the amount of antigen (active ingredient) per dose needed to achieve effective individual protection.
These newest vaccine purchases supplement the existing stockpile of 5.9 million doses of H5N1 vaccine and build on the department's plans to buy enough vaccine for 20 million people. This additional vaccine will be placed in the nation's Strategic National Stockpile where they will be available for use should an influenza pandemic occur.
HHS' effort to stockpile vaccine is part of a broader effort by the department to accelerate the development and production of new technologies for influenza vaccines within the U.S. Earlier this year, HHS announced a $1 billion investment to support the advanced development of cell-based production technologies for influenza vaccines and will help to modernize and strengthen the nation's influenza vaccine production by creating an alternative to producing influenza vaccines in eggs.
The H5N1 strain of avian flu has spread to more than 40 countries and has led to the deaths of hundreds of millions of additional birds, which has heightened concern about the possibility of a human flu pandemic. Furthermore, the number of avian flu cases in humans has reached more than 250 cases in 10 countries. More than half of those persons infected have died. To date, H5N1 avian influenza has remained primarily an animal disease, but should the virus acquire the ability for sustained transmission among humans, the potential for an influenza pandemic would have grave consequences for global public health.




http://www.hhs.gov/news/press/2006pres/20061120.html
 
Re: Washington Post Editorial Failure to Anticipate Vaccines & Tami Alternatives

These generalized vaccines are quickly becoming outmoded by the virus's evolution, not to mention that a significant percentage of the ones the US has already stockpiled have degraded and are no longer usable.
More and more, the government's arguments for getting a seasonal flu shot and for buying these bogus vaccines is to please the vaccine manufacturers sufficiently to keep them in business so they are able to crank out a proper vaccine when one exists.
This seems to be working insofar as they are sprucing up plants, even making new ones.
But perhaps a more direct subsidy is in order. Might cost less and would not burden consumers with confusion about seasonal flu shots, which --as recent studies attest -- just don't seem effective at reducing mortality.
I'm not against all vaccines. I got the pneumovax, but I do not get seasonal flu shots and I am not interested in receiving a generalized vaccine against some old H5N1 clade.
Be well, DA
 
Re: Washington Post Editorial Failure to Anticipate Vaccines & Tami Alternatives

DeadAhead said:
These generalized vaccines are quickly becoming outmoded by the virus's evolution,

This is not what I understand is the discussion. The vax will affect a main viral function and thus be generic as all virus must perform that function. That's the holy grail. It's far away, probably way after the next pandemic if that occurs in the next half decade.
 
Back
Top